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Abstract
Objective: To examine the frequency and phenotype of Th17 cells in the peripheral blood of early RA (eRA) patients.
Methods: CD4+ T cells were isolated from the peripheral blood of 33 eRA patients, 20 established RA patients and 53
healthy controls (HC), and from the synovial fluid of 20 established RA patients (RASF), by ficoll-hypaque gradient and
magnetical negative selection. After polyclonal stimulation, the frequency of Th17 and Th1 cells was determined by flow
cytometry and concentrations of IL-17, IFN-c, TNF-a and IL-10 were measured by ELISA in cell-free supernatants.
Results: When all of our eRA patients were analyzed together, a significantly lower percentage of circulating Th17 cells and
a lower CD4-derived IL-17 secretion were observed in comparison with HC. However, after stratifying by anti-CCP antibody
status, circulating Th17 cells were decreased in anti-CCP(+) but not in anti-CCP(-)-eRA. All Th17 cells were CD45RO+CD45RA-
and CCR6+. Dual Th17/Th1 cells were also exclusively decreased in anti-CCP(+)-eRA. Circulating Th17 and Th17/Th1 cells
were negatively correlated with anti-CCP titres. When anti-CCP(+)-eRA patients were retested one year after initiating
treatment with oral methotrexate, their circulating Th17 frequency was no longer different from HC. Of note, the
percentage of circulating Th1 cells and the secretion of CD4-derived IFN-c, TNF-a and IL-10 were not different between eRA
patients and HC. In established RA patients, circulating Th17 and T17/Th1 cell frequencies were comparable to HC. In RASF,
both Th17 and Th1 cells were increased when compared with blood of eRA patients, established RA patients and HC.
Conclusion: Decreased circulating Th17 levels in eRA seem to be a marker of anti-CCP seropositivity, and return to levels
observed in healthy controls after treatment with methotrexate.
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Introduction
RA, a systemic autoimmune disease, is characterized by chronic
joint inflammation, cartilage destruction and bone erosions.
Numerous experimental data indicate that IL-17A (henceforth
referred to as IL-17) plays an important role in the pathogenesis of
RA [1]. IL-17-deficient mice demonstrate a markedly attenuated
form of collagen-induced arthritis (CIA) [2], neutralization of IL-
17 during induction of experimental arthritis suppresses the onset
of disease [3], and anti-IL-17 therapy in established CIA is
associated with a significant reduction of severity [4]. IL-17 is
implicated in the development of bone erosions by altering the
RANKL/OPG balance [5], and its action may be independent of
TNF-a [6,7]. In human studies, IL-17 is spontaneously produced
by RA synovial membrane cultures [8], high levels have been
observed in the synovial fluid of patients with RA [8,9], IL-17
producing CD4+ T cells have been detected in RA synovial
membranes [10–12] and neutralization of IL-17 seems to be
effective in RA clinical trials [13]. Several sources of IL-17 have
been described: Th-17 cells, which are a subset of CD4+ helper T
cells, mast cells, NK cells and cd T cells, and all of them may
contribute to the pathogenesis of inflammatory arthritis [14–17].
An altered percentage of Th17 cells has been described in the
peripheral blood and synovial fluid of RA patients, but to date
conflicting data have been reported [18–25].
Our objective was to examine the frequency and phenotype of
Th17 cells in the peripheral blood of early RA patients, and in the
synovial fluid of patients with established RA. We were also
interested in determining which cell type is the main producer of
IL-17 in eRA peripheral blood and RA synovial fluid. Our early
arthritis clinic allowed the study of T cells from early RA patients
who have not received disease modifying drugs (DMARDs) or
steroids, thereby minimizing interference of drugs with ex vivo T
cell responses.
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Patients and Methods
Ethics Statement
The study was approved by the Hospital La Paz - IdiPAZ Ethics
Committee, and all subjects provided written informed consent.
Patients
Peripheral blood was obtained from 33 early RA patients and
from 33 age and sex-matched healthy controls. Early RA patients
fulfilled at least four 1987 American College of Rheumatology
criteria [26], had never received disease-modifying drugs or
corticosteroids, and had a disease duration of less than 6 months.
La Paz University Hospital in Madrid, Spain, has a monographic
clinic that takes care of early arthritis patients referred from a wide
primary care area, and this facilitated recruitment of untreated
early RA patients for the present study. Among early RA patients
there were 3 male and 30 female, 17 (52%) tested positive for IgM
rheumatoid factor, and 15 (45%) tested positive for anti-CCP
antibodies; their age was 53.4+13.1 years (mean + SD), and disease
activity score 28 (DAS28) [27] at first evaluation was 4.8+1.4
(mean + SD).
Eight anti-CCP positive eRA patients donated blood for
a second time, one year after the initiation of treatment with oral
MTX and low-dose prednisone. At the time of the second blood
drawing, prednisone had been discontinued in all except for 2
patients, who were taking 2.5 mg dayly, and all of them were
taking oral MTX at doses of 10 to 25 mg. These patients were 1
male and 7 female, aged 51.63615.17 years (mean6 SD). 4 out of
these 8 subjects had achieved remission as defined by a DAS28
score below 2.6 [28]. The remaining four patients had experienced
a significant clinical improvement, with a decrease in the DAS28
of .2.0 points, but they still demonstrated significant disease
activity associated with a DAS28.2.6. Blood was also obtained
from the 8 healthy subjects who had previously acted as controls
for these patients.
Synovial fluid (SF) was obtained from the knee joints of 20
patients with established RA who were receiving treatment with
oral methotrexate (MTX) and low-dose prednisone; 13 of these
patients (65%) tested positive for IgM rheumatoid factor and 11
(55%) tested positive for anti-CCP antibodies. In addition,
peripheral blood was obtained from 20 patients with established
RA who were receiving treatment with oral methotrexate (MTX)
and low-dose prednisone, and from 20 age- and sex- matched
controls. 11 of these patients (55%) tested positive for IgM
rheumatoid factor and 11 (55%) tested positive for anti-CCP
antibodies.
Isolation of CD4+ T Cells
Mononuclear cells were isolated from human blood and
synovial fluid by density centrifugation over Ficoll-Paque Plus
(GE Healthcare, Chalfont St. Giles, United Kingdom). CD4+ T
cells were subsequently purified by negative selection in an
Automacs (Miltenyi Biotec, Bergisch Gladbach, Germany) using
the ‘‘CD4+ T Cell Isolation Kit II’’ from Miltenyi Biotec,
containing a cocktail of biotin-conjugated antibodies against CD8,
CD14, CD16, CD19, CD36, CD56, CD123, c/d TCR and
Glycophorin A, followed by anti-Biotin MicroBeads. Isolated
CD4+ T cells were 98% pure and free of detectable CD14+
monocytes, CD8+ T cells, CD56+ NK cells, CD19+ B cells, and
cd T cells.
T Cell StimulationImmediately after isolation, CD4+ T cells
were cultured and stimulated in 24-well plates (106 cells/well)
containing RPMI 1640 medium (Lonza) with 10% FCS, 2 mM L-
glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin and
50 mM 2-mercapto-ethanol (‘‘complete RPMI medium’’). Two
different activation strategies were undertaken. T cells were
stimulated for 16 h with phorbol myristate acetate (PMA) (10 nM)
and ionomycin (2 mM), in the presence or absence of 4 mM
monensin (all three from Sigma-Aldrich). In addition, cells were
cultured for 1–4 days in the presence of a soluble anti-CD3 IgE
subclass mAb (T3/4.E, Sanquin, Amsterdam, The Netherlands,
formerly CLB) (0.5 mg/ml) plus anti-CD28 (1 mg/ml) (BD
Pharmingen) and anti-CD49d mAbs (1 mg/ml) (BD Pharmingen),
and restimulated for the last 6 hours with PMA and ionomycin,
with or without monensin.
Intracellular Cytokine Staining, Surface Staining, and
Flow Cytometry
Fluorochrome-conjugated mAbs from BD Pharmingen were
used to examine the expression of the phenotypical markers CD3,
CD4, CD8, CCR6, CCR4, CD45RO and CD45RA. Surface IL-
23R was detected with a biotinylated goat anti-human IL-23R
antibody (R&D Systems), followed by a FITC labeled avidin (BD
Pharmingen). For intracellular cytokine staining, T cells were
washed with PBS/2% FCS/0.01% NaN3, permeabilized for
10 min with FACS permeabilizing solution 2 (BD Pharmingen),
washed again, and incubated on ice for 1 h with an APC-labelled
anti-IFN-c mAb (clone B27; BD Pharmingen), a phycoerythrin
(PE)-labelled anti-IL17A mAb (clone eBio64DEC17; eBioscience),
a FITC-labeled anti-TNF-a mAb (clone Mab11, BD Pharmin-
gen), a PE-labeled anti-IL10 mAb (clone B-T10, Miltenyi Biotech)
or fluorochrome-labeled isotype control mAbs. After washing once
with PBS/2% FCS/0.01% NaN3 and once with PBS, cells were
resuspended in 1% paraformaldehyde and analyzed in a FACS-
Calibur flow cytometer using CellQuest software (BD Biosciences).
ELISAs
Cell-free culture supernatants were collected and stored at -
80uC. ELISAs for IL-17A were performed using a kit from
eBioscience. ELISAs for TNF-a, IL-10, and IFN-c were
performed using kits from BD Biosciences following the manu-
facturer’s instructions.
Statistical Analysis
Comparison between groups was by Mann-Whitney test. Paired
samples were compared using a Wilcoxon matched pairs signed
rank sum test. When appropriate, Bonferroni correction for
multiple comparisons was applied. Correlations were analyzed
using Spearman’s rank correlation coefficients. All analyses were
performed using Prism version 5.0 software (GraphPad Software).
Results
Expression of IL-17 by RA CD4+ T Cells
Our working hypothesis stated that the frequency of circulat-
ing Th17 cells in eRA would be increased. To our surprise, the
frequency of circulating Th17 cells was significantly decreased
among eRA patients (0.57%, 0.41–0.91%) (median, interquartile
range) in comparison with healthy controls (1.02%, 0.76–1.51%)
(Fig. 1A, B). At the same time, the percentage of Th17 cells in
the peripheral blood of patients with established RA (0.96%,
0.77–1, 79%) was not different from controls. In contrast, an
augmented frequency of Th17 cells was found in the synovial
fluid of established RA patients (2.20%, 0.91–3.46%) when
compared with circulating frequencies in controls, in eRA and in
established RA patients (Fig. 1A, B). All of the Th17 cells
expressed the memory phenotypical marker CD45RO, were
negative for CD45RA and positive for CCR6 expression
Th17 CD4+ T Cells in Early Rheumatoid Arthritis
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(Fig. 1C). The expression of IL-23R and of CCR4 could not be
analyzed together with IL-17 since these two molecules are
downregulated upon stimulation with PMA/ionomycin. Impor-
tantly, the proportion of circulating total CD4+ T cells was not
different between eRA and control subjects.
In parallel, the concentration of IL-17 detected by ELISA in
culture supernatants of stimulated eRA CD4+ T cells (1247, 472–
1911 pg/ml) was significantly decreased when compared with
healthy controls (2453, 1455–4012 pg/ml) (Fig. 1D), and this was
apparent not only when cells were stimulated overnight with
PMA/ionomycin (see above data) but also after stimulation for 4
days with anti-CD3/CD28/CD49d (976, 383–2451 pg/ml for
eRA vs 2130, 1019–3525 pg/ml for controls) (Fig. 1D). At the
same time, the secretion of IL-17 from peripheral blood CD4+ T
cells of established RA patients was not different from controls
(2594, 1693–3813 pg/ml after a 16 h stimulation and 2593, 1734–
4088 pg/ml after a 4-day stimulation). In contrast, CD4+ T cells
from the synovial fluid of established RA patients showed an
augmented secretion of IL-17 to the medium (6757, 3724–
19800 pg/ml after a 16 h stimulation and 6933, 4128–11420 pg/
ml after a 4-day stimulation), when compared with CD4+ T cells
from the peripheral blood of eRA patients, established RA patients
and controls (Fig. 1D).
Because several reports describe the production of IL-17 by
other cell populations (14–17), we additionally isolated cd T cells,
CD8 T cells and NK cells from patients and controls. We could
not detect any IL-17 by cytometry or ELISA in these cell subsets
from the synovial fluid of RA or from the peripheral blood of eRA,
established RA or healthy subjects. Moreover, after thorough
depletion of CD4+ T cells from PBMCs, no IL-17 could be
Figure 1. Expression of IL-17A by RA CD4+ T cells. CD4+ T cells were isolated from the peripheral blood of healthy controls (HCPB) (n = 53), the
peripheral blood of early RA patients (eRAPB) (n = 33), the peripheral blood of established RA patients (RAPB) (n = 20) and the synovial fluid of
established RA patients (RASF) (n = 20), and stimulated with PMA/Ionomycin for 16 h or with anti-CD3/CD28/CD49d for 4 days. A, B. Percentage of
CD4+ T cells expressing IL-17A (Th17 cells) after a 16 h stimulation, as determined by flow cytometry. Because the CD4 molecule is downregulated
upon stimulation with PMA, shown is CD3 expression on isolated CD4+ T cells. C. Representative flow cytometry dot-plots showing expression of
CD45RO, CD45RA and CCR6 versus IL-17A in isolated CD4+ T cells. D. Secretion of IL-17A to the culture medium of CD4+ T cells stimulated for 16 h
with PMA/ionomycin or for 4 days with anti-CD3/CD28/CD49d. Box-plots represent the median and interquartile range of all studied subjects,
whiskers represent the maximum and minimum values. *p,0.05 vs HCPB; { p,0.05 vs RAPB; ¥ p,0.05 vs eRAPB.
doi:10.1371/journal.pone.0042189.g001
Th17 CD4+ T Cells in Early Rheumatoid Arthritis
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detected in culture supernatants after short or long-term stimu-
lation periods, in agreement with work published by Shen et al
[29].
Expression of IFN-c, TNF-a and IL-10 by RA CD4+ T Cells
Interestingly, the frequency of circulating CD4+ T cells
producing IFN-c (Th1) was comparable between eRA (11.88,
8.22–17.50%) (median, interquartile range) and control subjects
(16.58, 9.25–22.64%) (Fig. 2A, B). In addition, no differences were
observed between these two groups when determining IFN-c,
TNF-a and IL-10 in supernatants of stimulated CD4 T cells
(Fig. 2C, D). In contrast, when compared with CD4+ T cells from
the peripheral blood of controls or eRA, augmented frequencies of
Th1 cells together with an augmented secretion of CD4-derived
IFN-c, TNF-a or IL-10 were observed in the synovial fluid of
established RA patients (Fig. 2, A-D).
Frequency of Th17/Th1 Cells in RA
The percentage of cells simultaneously producing IL-17 and
IFN-c (Th17/Th1 cells) [30], was significantly lower in eRA
patients (0.05, 0.04–0.13%) when compared with healthy controls
(0.14, 0.09–0.20%) (median, interquartile range) (Fig. 3A, B). In
contrast, the circulating Th17/Th1 frequency in patients with
established RA (0.16, 0.09–0.26%) was not different from controls.
At the same time, the percentage of Th17/Th1 cells was higher in
RA synovial fluid (0.93, 0.27–1.15%) when compared with the
peripheral blood of controls, of eRA patients and of established
RA patients (Fig 3A, B).
Figure 2. Expression of IFN-c, TNF-a and IL-10 by RA CD4+ T cells. CD4+ T cells were isolated from the peripheral blood of healthy controls
(HCPB) (n = 33), the peripheral blood of early RA patients (eRAPB) (n = 33) and the synovial fluid of established RA patients (RASF) (n = 20), and
stimulated with PMA/Ionomycin for 16 h or with anti-CD3/CD28/CD49d for 4 days. A, B. Percentage of CD4+ T cells expressing IFN-c (Th1 cells) after
a 16 h stimulation, as determined by flow cytometry. Because the CD4 molecule is downregulated upon stimulation with PMA, shown is CD3
expression on CD4+ T cells. C. Secretion of IFN-c by CD4+ T cells stimulated for 16 h with PMA/ionomycin or for 4 days with anti-CD3/CD28/CD49d. D.
Secretion of TNF-a and of IL-10 by CD4+ T cells stimulated for 16 h with PMA/ionomycin. Box-plots represent the median and interquartile range of
all studied subjects, whiskers represent the maximum and minimum values. *p,0.05 vs HCPB; { p,0.05 vs eRAPB.
doi:10.1371/journal.pone.0042189.g002
Th17 CD4+ T Cells in Early Rheumatoid Arthritis
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Relation of Circulating Th17 Cells with Clinical and
Analytical Parameters in eRA
We then decided to analyze the relation of the circulating Th17
and Th17/Th1 frequencies with clinical and analytical parameters
in early RA. The most striking observation came after subdividing
eRA patients into two groups based on the anti-CCP antibody
status. Anti-CCP positive eRA patients had a significantly lower
frequency of Th17 (0.44, 0.33–0.70%) and of Th17/Th1 cells
(0.04, 0.03–0.05%) in their peripheral blood when compared with
healthy controls (as noted above, Th17: 1.02%, 0.76–1.51% and
Th17/Th1 0.14, 0.09–0.20%) (Fig. 4A). Remarkably, the
percentage of circulating Th17 (0.70, 0.48–1.43%) and of
Th17/Th1 (0.07, 0.04–0.18%) cells in anti-CCP negative eRA
patients was not statistically different from controls (Fig. 4A). Of
note, in established RA, the circulating Th17 and Th17/Th1
frequencies were not different from controls, for both anti-CCP+
(Th17 0.95, 0.59–1,69%, Th17/Th1 0.15, 0.08–0.29) and anti-
CCP- (Th17 1.31, 0.77–1.99, Th17/Th1 0.17, 0.1–0.28) patients.
Interestingly, among anti-CCP+ eRA patients, a significantly
negative correlation was observed between the titre of anti-CCP
antibodies and the frequency of circulating Th17 cells, and also
between the titre of anti-CCP antibodies and the frequency of
circulating Th17/Th1 cells (Fig. 4B). No such correlation was
observed among anti-CCP+ patients with established RA.
When dividing eRA subjects according to the presence or
absence of basal bone erosions in X-rays of the hands and feet,
a significantly lower frequency of circulating Th17 and Th17/Th1
cells was observed in patients with erosive (Th17 0.43, 0.22–
0.51%; Th17/Th1 0.03, 0.01–0.04%) versus patients with non-
erosive disease (Th17 0.69, 0.41–1.02%; Th17/Th1 0.06, 0.04–
0.16%) (Fig. 4C). However, after adjusting for anti-CCP antibody
status it was evident that this was linked to the strong relation
between anti-CCP antibodies and erosions [31]. In fact, the
percentage of patients presenting with erosive disease was much
higher in anti-CCP+ (57%) versus anti-CCP- eRA (6%) (Fig. 3D);
in addition, among anti-CCP+ eRA subjects, a significantly higher
titre of anti-CCP antibodies was observed in those presenting with
erosions (2993, 1628–3200 IU/ml) versus patients without basal
erosions (199, 164–596 IU/ml) (Fig. 4D).
No differences in circulating Th17 or Th17/Th1 cells were
observed between RF(+) and RF(-) eRA or established RA
patients. Also, no significant correlations were observed between
the frequency of circulating Th17 cells and the titre of RF, DAS 28
score, age, ESR, or CRP, in eRA or established RA patients.
In vivo Effect of Treatment on the Circulating Th17 and
Th17/Th1 Frequencies
Interestingly, when re-evaluated after one year and when
patients were receiving treatment with oral MTX with or without
low-dose prednisone, the frequencies of circulating Th17 and of
circulating Th17/Th1 cells in anti-CCP+ eRA subjects were no
longer different from controls (Fig. 5A, B), and this was observed
not only in patients who had achieved remission but also in
patients who had persistent disease activity. Experimental varia-
tion in healthy controls was minimal when comparing data
obtained in the first versus the second visit (Fig. 5A, B).
Discussion
Several previous studies indicate that Th17 cells may play an
important role in the pathogenesis of RA [1–13]; therefore we
hypothesized that their numbers might be augmented in eRA
patients. We surprisingly detected a significantly decreased
frequency of circulating Th17 cells when analyzing all of our
patients with eRA as a single group, whereas established RA patients
showed circulating Th17 frequencies that were not different from
controls. Remarkably, after dividing eRA patients according to the
presence or absence of anti-CCP antibodies, it was evident that only
anti-CCP positive eRA patients demonstrated a decreased circulat-
ing Th17 population; in contrast, the frequency of circulating Th17
cells in anti-CCP negative eRA was comparable to the one observed
in healthy controls. That is, despite the fact that anti-CCP+ patients
represent 45% of our eRA population sample, their markedly
decreased Th17 frequency is able to bring down the final numbers in
the total eRA group, low enough to result in a significant difference
Figure 3. Proportion of Th17/Th1 cells in RA. CD4+ T cells were isolated from the peripheral blood of healthy controls (HCPB) (n = 53), the
peripheral blood of early RA patients (eRAPB) (n = 33), the peripheral blood of established RA patients (RAPB) (n = 20) and the synovial fluid of
established RA patients (RASF) (n = 20). A, B. Percentage of CD4+ T cells expressing both IL-17A and IFN-c (Th17/Th1 cells) after a 16 h stimulation
with PMA/ionomycin, as determined by cytometry. Box-plots represent the median and interquartile range of all studied subjects, whiskers represent
the maximum and minimum values. *p,0.05 vs HCPB; { p,0.05 vs RAPB; ¥ p,0.05 vs eRAPB.
doi:10.1371/journal.pone.0042189.g003
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in comparison with healthy controls. At the same time, the frequency
of total peripheral blood CD4+ T cells, the frequency of circulating
Th1 cells, and the secretion of CD4-derived IFN-c, TNF-a and IL-
10, were not different between eRA patients and healthy controls.
Of note, the frequency of circulating Th17/Th1 cells was decreased
in the peripheral blood of anti-CCP+ but not anti-CCP- eRA
patients, consistent with recent observations indicating that IL-17+/
IFN-c+ double producers arise from Th17 and not from Th1 cells
[32].
Interestingly, among anti-CCP+ eRA patients, both the Th17
and the Th17/Th1 frequency were negatively correlated with the
titre of anti-CCP antibodies which further reinforces the link
between low Th17 counts and CCP seropositivity. In addition,
a significantly lower frequency of circulating Th17 and Th17/Th1
cells was observed in patients who presented with erosive versus
patients presenting with non-erosive eRA; however, after adjusting
for anti-CCP antibody status it was evident that this was linked to the
strong relation between anti-CCP antibodies and erosions [31].
We chose to analyze cells from the synovial fluid of RA as
representative cells from the RA inflammatory site: RA synovial
fluid T lymphocytes represent T cells that have reached the joint
through the peripheral blood, and have acquired an activated
phenotype by locally interacting with the inflamed synovial tissue,
where hyperplastic synovial fibroblasts and activated synovial
macrophages are abundant [33,34]. We observed that, when
compared with the peripheral blood of healthy subjects and of
patients with early or established RA, an increased frequency of
Th17 cells was present in RA synovial fluid, together with an
Figure 4. Relation of Th17 and Th17/Th1 frequencies with anti-CCP antibodies and with erosions in eRA. A. Percentage of Th17 and
Th17/Th1 cells among CD4+ T cells isolated from the peripheral blood of healthy controls (HCPB) (n = 53), the peripheral blood of anti-CCP+ eRA
patients (ACCP+) (n = 15) and the peripheral blood of anti-CCP- eRA patients (ACCP-) (n = 18). *p,0.05 vs HCPB. B. Linear correlation between the
percentage of circulating Th17 or Th17/Th1 cells and the anti-CCP antibody titre in anti-CCP+ eRA patients. C. Frequencies of Th17 and Th17/Th1 cells
in the peripheral blood of eRA patients with erosive (n = 9) or non-erosive disease (n = 24) at initial presentation. *p,0.05 vs patients with erosive
disease. D. Left panel: Percentage of patients with erosive disease at initial presentation among anti-CCP+ and anti-CCP- eRA subjects; Right panel:
anti-CCP antibody titres in anti-CCP+ eRA patients with erosive or non-erosive disease at initial presentation. *p,0.05 vs patients with erosive disease.
Box-plots represent the median and interquartile range of all studied subjects, whiskers represent the maximum and minimum values.
doi:10.1371/journal.pone.0042189.g004
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increased frequency of Th17/Th1 cells. This is consistent with a set
of previous studies on RASF Th17 frequencies [19,24] but
discordant with others [22]. That is, Th17 cells seem to be
concentrated in the RA inflammatory focus but spreading of
potentially pathogenic Th17 cells through the peripheral blood is
limited or decreased, which could be related to increased
migration followed by sequestration in the inflamed joint [35].
This situation may be reversed following treatment; in fact, it has
been reported that anti-TNF therapy in RA is associated with an
increased percentage of circulating Th17 cells possibly attributable
to a decreased homing to the synovium [18].
We were particularly interested in examining IL-17 production
by other cell populations, such as cd T cells, CD8 T cells and NK
cells, but observed that this cytokine was exclusively produced by
CD4+ T cells in RA synovial fluid and in the peripheral blood of
healthy controls, eRA and established RA patients, consistent with
work published by Shen et al [29].
Th17 biology is complex and incompletely understood, which
may explain why previous reports on the frequency of Th17 cells
in RA have yielded conflicting results. Some authors have found
increased circulating Th17 frequencies [20,21,24,25] whereas
others report comparable frequencies to those displayed by healthy
controls [18,19,22]. Discordances among studies may be due in
part to differences in the clinical profile and/or medications of
patients. Whereas an influence of immunomodulating drugs on
the ex vivo behavior of isolated cells is possible [18], the effect of
perpetuating inflammatory feedback loops that are effective as
disease progresses may also be a player.
Our population of subjects with early disease and who had
never received corticosteroids or DMARDs was not homogeneous
when considering the frequency of circulating Th17 cells. A clear
difference between anti-CCP+ and anti-CCP- eRA patients was
observed, and a ready explanation for this observation is not
apparent at present. In fact, the data reported herein may
contribute to reinforce the notion that anti-CCP+ and anti-CCP-
RA are distinct entities [36].
The different circulating Th17 and Th17/Th1 cell frequencies
in patients with early versus established RA suggests that the
immune mechanisms mediating early phases of the disease may be
different from those implicated in more advanced stages [37].
Interestingly, when our anti-CCP+ eRA patients were re-
examined one year after the first visit, while receiving treatment
with oral MTX, their circulating Th17 frequency was no longer
different from controls. This was apparent not only in patients who
had achieved remission but also in patients who had persistent
disease activity, which suggests that medication may be playing
a role. Other investigators have concluded that the peripheral
blood Th17 frequency in RA may be modified by therapy. As
noted above, Aerts et al [18] reported that in established RA the
peripheral Th17 cell frequency is not elevated, but anti-TNF
therapy induces a striking increase of circulating Th17 cells and
IL-17 production, irrespective of disease activity. In addition,
Notley et al [38] found that in collagen-induced arthritis, TNF
blockade resulted in reduced arthritis severity but, unexpectedly,
expanded populations of extra-articular Th17 cells, which were
shown by adoptive transfer to be pathogenic.
Finally, recently published phase II clinical trials on the efficacy
of IL-17 blockade in RA have yielded conflicting results [39,40].
In light of our findings, discrepancies could be related to
differences in the stage of disease or anti-CCP antibody status of
patients.
Conclusion
In summary, we have observed a significantly decreased
frequency of circulating Th17 and Th17/Th1 cells in anti-
CCP+ eRA patients that returns to values observed in controls
during follow-up after initiating treatment with MTX. The basal
circulating Th17 frequency was significantly correlated with the
titre of anti-CCP antibodies and with the presence or absence of
basal erosions. At the same time, the basal Th17 and Th17/Th1
frequency in anti-CCP- eRA patients was not different from
controls. This indicates that further studies are needed to fully
understand the complex biology of Th17 cells in RA. In addition,
the percentage of circulating Th17 cells in eRA can be considered
as a marker of CCP positivity.
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Figure 5. In vivo effect of treatment on the circulating Th17 and Th17/Th1 frequencies. Eight patients with anti-CCP+ eRA donated blood
for a second time, one year after the first visit, and while receiving treatment with oral MTX with or without low-dose prednisone. Four out of these
patients had achieved remission and 4 of them demonstrated persistent disease activity. Shown are the frequencies of circulating Th17 and Th17/Th1
cells in patients who achieved remission (ACCP+ remission) (n = 4), in patients who did not achieve remission (ACCP-non-remission) (n = 4) and in
their age and sex-matched controls (HCPB) (n = 8), observed at first evaluation (‘‘before treatment’’) and at the one-year follow-up visit (‘‘after
treatment’’). Box plots represent the median and interquartile range of all studied subjects, whiskers represent the maximum and minimum values.
*p,0.05 vs HCPB.
doi:10.1371/journal.pone.0042189.g005
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